Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-113140
Abstract: Immunotherapy is emerging as a potent therapy for a range of hematologic malignancies including lymphomas. Indeed adoptive transfer of T cells genetically engineered to express the CD19 chimeric antigen receptor (CAR) has now received FDA… read more here.
Keywords: cell; equity ownership; marker equity; specific cells ... See more keywords